Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-Blind, Placebo-Controlled Evaluation of Avanafil for On-Demand Treatment of Men With Erectile Dysfunction

X
Trial Profile

A Randomized, Double-Blind, Placebo-Controlled Evaluation of Avanafil for On-Demand Treatment of Men With Erectile Dysfunction

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 15 Dec 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Avanafil (Primary)
  • Indications Erectile dysfunction
  • Focus Registrational; Therapeutic Use
  • Sponsors VIVUS
  • Most Recent Events

    • 15 Apr 2014 Primary endpoint 'Sexual-Encounter-Profile' has been met according to results presented at the 29th Congress of the European Association of Urology.
    • 15 Apr 2014 Results presented at the 29th Congress of the European Association of Urology.
    • 19 Jun 2013 Primary endpoint 'Intercourse-achieved' has been met, according to a VIVUS media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top